-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Metastatic Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Metastatic Colorectal Cancer Drug Details: Galinpepimut-S is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Metastatic Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Metastatic Ovarian Cancer Drug Details: Galinpepimut-S is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Galinpepimut-S in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Galinpepimut-S in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Galinpepimut-S in Triple-Negative Breast Cancer (TNBC) Drug Details: Galinpepimut-S...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vudalimab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vudalimab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vudalimab in Nasopharyngeal Cancer Drug Details: XmAb-717 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cefepime + Taniborbactam Hydrochloride) in Resistant Pseudomonas aeruginosa Infections
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (Cefepime + Taniborbactam Hydrochloride) in Resistant Pseudomonas aeruginosa Infections Drug Details: Fixed dose combination of...
-
Product Insights
NewDuctal Carcinoma – Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Ductal Carcinoma is early stage of breast cancer where the ductal cells of the breast tissue tend to multiply or grow uncontrollably without any evidence of metastatic. If not treated in initial stages, this could be invasive. Ductal carcinoma is represented in 4 different stages, pre invasive, non-invasive, ductal intraepithelial neoplasia, intra ductal cancer. In invasive form spread of cancer cells into...
-
Product Insights
NewMammary Ductal Carcinoma – Drugs In Development, 2024
Empower your strategies with our Mammary Ductal Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma is a type of breast cancer that occurs in the milk ducts and moves into nearby tissues. There are two types of ductal carcinoma, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS). If the abnormal cancer cells are seen inside the milk ducts, then it is DCIS. DCIS is also known as intraductal carcinoma or non-invasive ductal...
-
Product Insights
NewDuctal Carcinoma In Situ – Drugs In Development, 2024
Empower your strategies with our Ductal Carcinoma In Situ – Drugs In Development, 2024 report and make more profitable business decisions. Ductal carcinoma in situ (DCIS), also referred to as intraductal carcinoma, is a non-invasive breast cancer characterized by a proliferation of abnormal epithelial cells confined within the basement membrane. Disruption of the basement membrane layer would change the diagnosis from DCIS to invasive breast cancer. DCIS is considered to be a precursor for invasive breast cancer. The Ductal Carcinoma In...
-
Product Insights
NewRhabdomyosarcoma – Drugs In Development, 2024
Empower your strategies with our Rhabdomyosarcoma – Drugs In Development, 2024 report and make more profitable business decisions. Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy,...